Valuation: Avalo Therapeutics, Inc.

Market Cap 862M 747M 706M 641M 1.2B 82.68B 1.21B 8.43B 3.26B 41.93B 3.24B 3.17B 134B P/E 2026 *
-5.67x
P/E 2027 * -5.85x
Enterprise Value 438M 379M 359M 326M 610M 42B 614M 4.28B 1.65B 21.3B 1.64B 1.61B 67.91B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.07%
Yield 2027 * -
1 day+3.17%
1 week-8.95%
Current month-14.27%
1 month-16.89%
3 months+15.70%
6 months+3.50%
Current year-8.70%
1 week 15.39
Extreme 15.39
18.14
1 month 15.39
Extreme 15.39
21.02
Current year 12.51
Extreme 12.51
24.27
1 year 9.84
Extreme 9.84
24.27
3 years 3.39
Extreme 3.39
52.75
5 years 3.39
Extreme 3.39
7,401.54
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Exercice

Chief Financial Officer

30,555 0.0570%
28/8/26 Exercice

Chief Technology Officer

2,037 0.0038%
18/8/26 Exercice

Chief Financial Officer

93,093 0.1736%
Change 5-day change 1-year change 3-year change Capi.($)
+3.17%-8.95%+69.88%-44.02% 862M
+0.66%+0.87%+47.39%+97.63% 69.18B
-1.19%-1.99%+33.01%+73.08% 62B
+2.22%-4.83%-15.32%+361.69% 26.19B
+1.46%+1.30%+28.58%+13.76% 25.75B
-0.89%-2.34%-3.46%-12.11% 24.29B
+2.84%+2.12%+24.28%-17.13% 19.84B
0.00%-14.23%+170.04%+298.75% 15.65B
-0.57%-1.37%-4.53%+855.80% 13.88B
-0.39%-5.61%-9.51%+483.04% 14.09B
Average +0.68%-3.56%+34.04%+211.05% 27.17B
Weighted average by Cap. +0.29%-1.04%+31.59%+161.19%

Financials

2026 *2027 *
Net sales - -
Net income -111M -96.37M -91.09M -82.69M -155M -10.67B -156M -1.09B -420M -5.41B -418M -408M -17.25B -133M -115M -109M -98.53M -185M -12.71B -186M -1.3B -501M -6.45B -498M -487M -20.55B
Net Debt -424M -367M -347M -315M -591M -40.68B -594M -4.15B -1.6B -20.63B -1.59B -1.56B -65.76B -306M -265M -250M -227M -426M -29.31B -428M -2.99B -1.15B -14.87B -1.15B -1.12B -47.39B
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
17/09/26 USD 16.58 +3.17% 1,443,197
15/09/26 USD 16.07 -0.68% 1,102,765
14/09/26 USD 16.18 +0.37% 908,424
11/09/26 USD 16.12 -6.17% 2,525,470
10/09/26 USD 17.18 -5.66% 913,754
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
16.07USD
Average target price
44.08USD
Spread / Average Target
+174.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!